The White House is highlighting a 3.1% decrease in prescription drug prices over the past year, asserting it is the steepest drop recorded since 1963 and a direct result of President Trump's initiatives. An administration statement declared, "Trump promised to slash prescription drug prices — and he has delivered."
The White House attributed the decline to the administration's "Most Favored Nation" policies. During the past year, President Trump engaged in strong negotiations with major pharmaceutical companies, securing reduced prices for government programs like Medicare and Medicaid. A new platform, "TrumpRx," was established to offer discounts to individuals paying out-of-pocket.
These concessions were reportedly achieved by threatening the pharmaceutical industry with significant tariffs if they did not align their prices with those in other major industrialized nations. President Trump has frequently cited the reduction in drug costs as a key achievement that could sway voters in the upcoming midterm elections.
Several major drug manufacturers, including Pfizer, pledged to implement discounts. Pfizer committed to offering "TrumpRx" discounts on various products. These included an 85% reduction for the menopause pill Duavee, bringing the cost to approximately $30, and an 85% cut for Toviaz, used to treat overactive bladders, reducing its price to $42. The company also lowered the price of the eczema ointment Eucrisia by 80%, to $162 per tube, and offered a 50% discount on the migraine drug Zavzpret, making its monthly cost about $600 without insurance. A 40% discount was also applied to the rheumatoid arthritis drug Xeljanz, lowering monthly costs to $3,644.
These agreements, some of which Congress is considering codifying, follow recent efforts by former President Joe Biden's administration to renegotiate Medicare prices for common drugs. White House spokesman Kush Desai dismissed claims that Biden's actions contributed to the price declines as "idiotic and unfounded."
President Trump has made his economic policies, including tax cuts and the impact of a strong stock market on retirement accounts, a central theme of his campaign for the midterm elections. He has characterized recent increases in gasoline prices and inflation as temporary. The administration has also indicated potential future actions, with Trump threatening to engage with health insurance executives to address corporate profits. Internal polling reportedly suggests that pressure on the pharmaceutical industry could benefit Republican candidates.